Jörg J. Möhrle

Swiss Tropical and Public Health Institute — Switzerland

Medicine · Health Sciences

31h-index3.6kcitations70works4.52yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Malaria Research and Control(59), Computational Drug Discovery Methods(28), Mosquito-borne diseases and control(18), Drug-Induced Hepatotoxicity and Protection(15), Research on Leishmaniasis Studies(9)

Publications70 total

A roadmap for understanding sulfadoxine-pyrimethamine in malaria chemoprevention
Parasitology·2025· 6 citedOpen Access
Characterizing the pharmacological interaction of the antimalarial combination artefenomel-piperaquine in healthy volunteers with induced blood-stage Plasmodium falciparum to predict efficacy in patients with malaria
BMC Medicine·2024· 4 citedOpen Access
Addressing health equity for breastfeeding women: primaquine for Plasmodium vivax radical cure
Malaria Journal·2024· 5 citedOpen Access
How long does it take to develop a new drug?
The Lancet Regional Health - Europe·2024· 5 citedOpen Access
PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies
Clinical and Translational Science·2024· 4 citedOpen Access
Characterizing the pharmacological interaction of the antimalarial combination artefenomel-piperaquine in healthy volunteers with induced blood stage <i>Plasmodium falciparum</i>
2024· 3 citedOpen Access
Using Cryopreserved Plasmodium falciparum Sporozoites in a Humanized Mouse Model to Study Early Malaria Infection Processes and Test Prophylactic Treatments
Microorganisms·2023· 5 citedOpen Access
Development and application of a PBPK modeling strategy to support antimalarial drug development
CPT Pharmacometrics & Systems Pharmacology·2023· 18 citedOpen Access
Moving seasonal malaria chemoprevention out of its geographical isolation
The Lancet Infectious Diseases·2023· 2 cited
A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria
CPT Pharmacometrics & Systems Pharmacology·2022· 3 citedOpen Access
New <i>In Vitro</i> Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations
Antimicrobial Agents and Chemotherapy·2022· 13 citedOpen Access
Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs
American Journal of Tropical Medicine and Hygiene·2022· 9 citedOpen Access
Parasite Viability as a Measure of <i>In Vivo</i> Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
Antimicrobial Agents and Chemotherapy·2022· 9 citedOpen Access
Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
LSTM Online Archive (Liverpool School of Tropical Medicine)·2022· 30 cited
Effect of novel antimalarial ZY-19489 on Plasmodium falciparum viability in a volunteer infection study
The Lancet Infectious Diseases·2022· 6 citedOpen Access
A new <i>in vitro</i> checkerboard-parasite reduction ratio interaction assay for early de-risk of clinical development of antimalarial combinations
2022· 2 citedOpen Access
Model-informed target product profiles of long-acting-injectables for use as seasonal malaria prevention
PLOS Global Public Health·2022· 22 citedOpen Access
Model-informed target product profiles of long-acting- injectables for use as seasonal malaria prevention: code and simulation data
Zenodo (CERN European Organization for Nuclear Research)·2022Open Access
Model-informed target product profiles of long-acting- injectables for use as seasonal malaria prevention: code and simulation data
PLOS Global Public Health·2022Open Access
Simultaneous Estimation of Zy-19489 and Its Active Metabolitezy-20486 in Human Plasma Using Lc–Ms/Ms, a Novel Antimalarial Compound
Bioanalysis·2021· 3 cited
page 1 of 4Next →

Frequent Co-authors

James McCarthy(22), Stephan Chalon(15), Stephan Duparc(14), Louise Marquart(14), Nathalie Gobeau(12), Paul Griffin(9), Rob Hooft van Huijsduijnen(8), Suzanne Elliott(7), Jeremy N. Burrows(6), Timothy N. C. Wells(6), Mark Baker(6), Thomas Rückle(6), Katharine A. Collins(6), Peter O’Rourke(5), Fiona Macintyre(4), Silvana Sekuloski(4), David A. Fidock(4), Azrin N. Abd‐Rahman(4), Melissa A. Penny(4), Winston E. Gutteridge(3)